A phase I, open-label, single-centre study to evaluate the absorption, distribution, metabolism and excretion (ADME) of oral [14C]-ibrexafungerp in healthy male subjects after repeat dosing
Latest Information Update: 30 Jun 2023
At a glance
- Drugs Ibrexafungerp (Primary)
- Indications Candidiasis; Invasive bronchopulmonary aspergillosis; Mycoses; Vulvovaginal candidiasis
- Focus Pharmacokinetics
- Sponsors SCYNEXIS
- 19 Dec 2022 New trial record
- 14 Dec 2022 Status changed from recruiting to completed.
- 14 Dec 2022 Status changed from not yet recruiting to recruiting.